Jinxin Fertility Group Limited (abbreviation: JXR) disclosed a fresh on-market share repurchase of 1.40 million ordinary shares on 14 September 2026.

• Transaction details – Repurchase volume: 1.40 million shares – Price range: HKD 2.10–2.14 per share – Volume-weighted average price: HKD 2.1206 per share – Aggregate consideration: HKD 2.98 million

• Impact on share capital – Issued shares (excluding treasury shares) fell 0.05 % from 2.69 billion to 2.68 billion. – Treasury stock rose to 20.87 million shares, now representing c. 0.78 % of total shares in issue (2.71 billion). – Total shares in issue remain unchanged because the 1.40 million repurchased shares have been transferred to treasury rather than cancelled.

• Ongoing cancellation pipeline Since 27 March 2026, JXR has accumulated 92.47 million shares for cancellation that were not yet cancelled as at 14 September 2026. This pool equates to roughly 3.44 % of the current issued share count, indicating further potential contraction of the free float once the formal cancellations are executed.

• Repurchase mandate utilisation The latest buy-back was conducted under the general mandate granted on 25 June 2026, which authorises JXR to repurchase up to 262.51 million shares. Cumulative repurchases held as treasury shares now total 33.41 million, utilising 1.27 % of the authorised limit.

• Moratorium in effect In line with HKEX Main Board Rule 10.06, JXR is restricted from issuing new shares or disposing of treasury shares until 14 October 2026, 30 days after the latest repurchase.

The continued execution of share repurchases underscores management’s active capital management strategy as the company progressively reduces its outstanding share base while retaining flexibility under the current mandate.